Abstract Book - PDF - San Antonio Breast Cancer Symposium

CTRC-AACR San Antonio Breast Cancer Symposium
P2-10-20 A tumor DNA complexity index is an independent predictor
of survival in a dataset of 1950 breast cancers; a METABRIC
group study
Vollan HKM, Rueda OM, Børresen-Dale A-L, Aparicio S, Caldas
C. Institute for Cancer Research, Oslo University Hospital, Oslo,
Norway; The K.G. Jebsen Center for Breast Cancer Research,
Institute for Clinical Medicine, University of Oslo, Norway; Oslo
University Hospital, Oslo, Norway; Cambridge Research Institute,
Cambridge, United Kingdom; University of Cambridge, United
Kingdom; University of British Colombia, Vancouver, BC, Canada;
British Colombia Cancer Research Center, Vancouver, BC, Canada;
Cambridge Experimental Cancer Medicine Centre, Cambridge,
United Kingdom; Addenbrooke’s Hospital, Cambridge University
Hospital, Cambridge, United Kingdom.
P2-10-21 Prognostic value of estrogen receptor status in women with
synchronous or metachronous breast cancers
Huo D. University of Chicago, IL.
P2-10-22 Phosphorylation of Steroid Receptor Coactivator 3 (SRC3)
at Ser543 is a novel independent prognostic marker in
breast cancer
Palmieri C, Gojis O, Rudraraju B, Abdel-Fatah TMA, Moore D, Shaw J,
Green A, Ellis IO, Coombes RC, Ali S. Imperial College London, United
Kingdom; Nottingham University City Hospital, Nottingham, United
Kingdom; University of Leicester, United Kingdom; Nottingham
University Hospitals, City Hospital Campus, Nottingham, United
Kingdom.
P2-10-23 Lymphovascular Invasion (LVI) and Overall Survival in
Node-negative and Node-positive Breast Cancer Patients:
A Meta-analysis
Sahebjam S, Diaz-Padilla I, Ocana A, Seruga B, Amir E. Princess
Margaret Hospital; Institute of Oncology Ljubljana.
P2-10-24 Independent validation of Recurrence Online using 1,638
breast cancer microarray samples
Györffy B, Weltz B, Benke Z, Timar J, Sztupinszki Z, Schaefer R.
Hungarian Academy of Sciences; Semmelweis University; Charité.
P2-10-25 Prognostic value of relative change in tumor marker CA 27.29
in early stage breast cancer – The SUCCESS trial
Hepp P, Tesch H, Forstbauer H, Rezai M, Beck T, Schrader I, Kleine-
Tebbe A, Hucke J, Finas D, Soeling U, Zahm D-M, Weiss E, Beckmann
MW, Janni W, Rack B. University Düsseldorf; Praxis Prof. Tesch
Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf;
Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim;
Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin
Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum
Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl &
Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen;
Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich.
P2-10-26 Association between circulating tumor cells and molecular
breast cancer subtypes
Gang N, Haibo W, Funian L, Chen L, Xiaoyi L, Xingang W, Zhidong L.
Affiliated Hospital of Medical College, Qingdao University, Qingdao,
Shandong, China.
P2-10-27 No Discordant Receptor Status Results among 50 Paired
Breast and Axillary Metastasis Core Biopsies when Pre-analytic
Variation is Controlled
Miller DV, Rosenthall RE, Avent JM, Carter CC, Hansen J, Hammond
MEH. Intermountain Healthcare, Salt Lake City, UT.
P2-10-28
P2-10-29
P2-10-30
P2-10-31
P2-10-32
P2-10-33
The Prognostic Index, KiGE, Combining Proliferation,
Histological Grade and Estrogen Receptor Status Challenges
Gene Profiling –
A Study in 1,854 Chemo-Naïve Women with N0/N1 Primary
Breast Cancer
Strand C, Bak M, Borgquist S, Chebil G, Falck A-K, Fjällskog M-L,
Grabau D, Hedenfalk I, Jirström K, Klintman M, Malmtröm P, Olsson
H, Rydén L, Stål O, Bendahl P-O, Fernö M. Lund University, Division
of Oncology, Skåne University Hospital, Lund, Sweden; Odense
University Hospital, Odense, Denmark; Mammography, Bergaliden,
Helsingborg, Sweden; Helsingborg Hospital, Helsingborg, Sweden;
Uppsala University Hospital, Uppsala, Sweden; Lund University,
Skåne University Hospital, Lund, Sweden; Lund University, Division of
Pathology, Lund, Sweden; Skåne University Hospital, Lund, Sweden;
Linköping University, County Council of Östergötland, Linköping,
Sweden; Lund University, Division of Surgery, Skåne University
Hospital, Lund, Sweden.
Time dependent breast cancer metastasis prediction using
novel biological imaging, clinico-pathological and genomic
data combined with Bayesian modeling to reduce over-fitting
and improve on inter-cohort reproducibility
Sheeba I, Kelleher M, Lawler K, Festy F, Barber P, Shamill E, Gargi P,
Weitsman G, Barrett J, Fruhwirth G, Huang L, Tullis I, Woodman N,
Pinder S, Ofo E, Fernandes L, Beutler M, Ameer-Beg S, Holmberg L,
Purushotham A, Fraternali F, Condeelis J, Hanby A, Gillett C, Ellis P,
Vojnovic B, Coolen A, Ng T. Kings College London, Guy’s Medical
School Campus, London, England, United Kingdom; King’s College
London, Strand Campus, London, England, United Kingdom; Guy’s
and St Thomas Foundation Trust, London, England, United Kingdom;
Gray Institute for Radiation Oncology & Biology, University of Oxford,
England, United Kingdom; Leeds Institute of Molecular Medicine,
Leeds, England, United Kingdom.
Expression of lipid metabolism genes in contralateral
unaffected breast associated with estrogen receptor status of
breast cancer
Wang J, Scholtens D, Holko M, Ivancic D, Lee O, Hu H, Chatterton RT,
Khan SA. Northwestern university, Chicago, IL.
Correlation of quantitative p95HER2 and total HER2 levels
with clinical outcomes in a combined analysis of two cohorts
of trastuzumab-treated metastatic breast cancer patients
Duchnowska R, Sperinde J, Leitzel K, Szostakiewicz B, Paquet A, Ali
SM, Jankowski T, Haddad M, Fuchs E-M, Arlukowicz-Czartoryska B,
Winslow J, Singer C, Wysocki PJ, Lie Y, Horvat R, Foszczynska-Kloda
M, Petropoulos C, Radecka B, Litwiniuk M, Debska S, Weidler J,
Huang W, Biernat W, Köstler WJ, Jassem J, Lipton A. Military Institute
of Medicine, Warsaw, Poland; Monogram Biosciences/Integrated
Oncology/LabCorp, South San Francisco, CA; Penn State/Hershey
Medical Center, Hershey, PA; Medical University of Gdansk, Poland;
Lublin Oncology Center, Lublin, Poland; Medical University of Vienna,
Austria; Bialystok Oncology Center, Bialystok, Poland; Greater Poland
Cancer Center, Poznan, Poland; West Pomeranian Oncology Center,
Szczecin, Poland; Opole Oncology Center, Opole, Poland; Poznan
University of Medical Sciences, Poznan, Poland; Regional Cancer
Center, Lódz, Poland.
Sialyl Lewis X and inflammatory mediators in breast cancer
patients: biological correlations and prognostic value
Lee B-N, Arun BK, Cohen EN, Tin S, Gutierrez-Barrera AM, Miura T,
Kiyokawa I, Alvarez RH, Valero V, Ueno NT, Cristofanilli M, Reuben JM.
University of Texas MD Anderson Cancer Center, Houston, TX; Nitto
Boseki Co., Ltd, Tokyo, Japan; Fox Chase Cancer Center,
Philadelphia, PA.
Mitotic Component of Grade Can Distinguish Breast Cancer
Patients at Greatest Risk of Local Relapse
Done SJ, Miller NA, Wei Shi W, Pintilie M, McCready DR, Liu F-F,
Fyles A. University Health Network, Toronto, ON, Canada; Princess
Margaret Hospital, University Health Network, Toronto, ON, Canada;
University of Toronto, ON, Canada.
Cancer Res; 72(24 Suppl.) December 15, 2012 26s Cancer Research